# A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )

> **NCT05176639** · PHASE3 · COMPLETED · sponsor: **Viridian Therapeutics, Inc.** · enrollment: 113 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** VRDN-001 Phase 3 Cohort (THRIVE)
- **DRUG:** VRDN-001 Placebo

## Key facts

- **NCT ID:** NCT05176639
- **Lead sponsor:** Viridian Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-03
- **Primary completion:** 2024-07-15
- **Final completion:** 2025-03-27
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176639, "A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )". Retrieved via AI Analytics 2026-09-11 from https://api.ai-analytics.org/clinical/NCT05176639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*